These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Rolo AP; Teodoro JS; Palmeira CM Free Radic Biol Med; 2012 Jan; 52(1):59-69. PubMed ID: 22064361 [TBL] [Abstract][Full Text] [Related]
8. Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis. van der Poorten D; George J Clin Liver Dis; 2008 Nov; 12(4):805-24, ix. PubMed ID: 18984468 [TBL] [Abstract][Full Text] [Related]
9. [Nonalcoholic steatohepatitis: pathogenesis and treatment]. Park SH Korean J Hepatol; 2008 Mar; 14(1):12-27. PubMed ID: 18367854 [TBL] [Abstract][Full Text] [Related]
10. Is the slippery slope from steatosis to steatohepatitis paved with triglyceride or cholesterol? Ginsberg HN Cell Metab; 2006 Sep; 4(3):179-81. PubMed ID: 16950134 [TBL] [Abstract][Full Text] [Related]
11. [Role of lipid peroxidation in non-alcoholic steatohepatitis]. Fraenkel E; Lazúrová I; Fehér J Orv Hetil; 2004 Mar; 145(12):611-8. PubMed ID: 15119115 [TBL] [Abstract][Full Text] [Related]
12. New concepts in the pathogenesis of alcoholic liver disease. Albano E Expert Rev Gastroenterol Hepatol; 2008 Dec; 2(6):749-59. PubMed ID: 19090736 [TBL] [Abstract][Full Text] [Related]
13. Hepatocyte specific deletion of c-Met leads to the development of severe non-alcoholic steatohepatitis in mice. Kroy DC; Schumacher F; Ramadori P; Hatting M; Bergheim I; Gassler N; Boekschoten MV; Müller M; Streetz KL; Trautwein C J Hepatol; 2014 Oct; 61(4):883-90. PubMed ID: 24845607 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis. Beraza N; Malato Y; Vander Borght S; Liedtke C; Wasmuth HE; Dreano M; de Vos R; Roskams T; Trautwein C Gut; 2008 May; 57(5):655-63. PubMed ID: 18408102 [TBL] [Abstract][Full Text] [Related]
15. [Non-alcoholic fatty liver disease--new view]. Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346 [TBL] [Abstract][Full Text] [Related]
16. c-Met confers protection against chronic liver tissue damage and fibrosis progression after bile duct ligation in mice. Giebeler A; Boekschoten MV; Klein C; Borowiak M; Birchmeier C; Gassler N; Wasmuth HE; Müller M; Trautwein C; Streetz KL Gastroenterology; 2009 Jul; 137(1):297-308, 308.e1-4. PubMed ID: 19208365 [TBL] [Abstract][Full Text] [Related]
17. Angiogenesis in chronic liver disease and its complications. Coulon S; Heindryckx F; Geerts A; Van Steenkiste C; Colle I; Van Vlierberghe H Liver Int; 2011 Feb; 31(2):146-62. PubMed ID: 21073649 [TBL] [Abstract][Full Text] [Related]
18. The relationship between apoptosis and non-alcoholic fatty liver disease: an evolutionary cornerstone turned pathogenic. Canbay A; Gieseler RK; Gores GJ; Gerken G Z Gastroenterol; 2005 Feb; 43(2):211-7. PubMed ID: 15700216 [TBL] [Abstract][Full Text] [Related]
20. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Neuschwander-Tetri BA Hepatology; 2010 Aug; 52(2):774-88. PubMed ID: 20683968 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]